Supplements and Heart Rhythm: The QT Safety Map

Most supplement safety questions are noisy: small studies, weak signals, contradictory meta-analyses. Cardiac repolarization is different. The QT interval is measurable on a 12-lead ECG, the hERG ion channel has a published mechanism, and the agencies that track adverse events (FDA, EMA, the Council for Responsible Nutrition reporting framework) have decades of pharmacovigilance data on which compounds trigger which kinds of cardiac events.

That makes this one of the few areas where a supplement-safety guide can be honest, specific, and useful. This article walks the named botanicals that show real hERG or QT signal in the literature, the drug-supplement combinations that drive most reported events, and the cardioprotective compounds whose evidence base actually holds up under scrutiny.

For prescription-side decisions about QT-prolonging drugs (azithromycin, ondansetron, methadone, citalopram, the antifungal-azole family, several antipsychotics), see our sister site OmniRx's clinical decision guide on ibogaine and cardiac safety, which covers the underlying QT pharmacology in clinical-decision-support depth.

Why QT interval and hERG matter

The QT interval on an electrocardiogram measures the time it takes a ventricular cell to depolarize, contract, and re-polarize so it can fire again. When that interval lengthens, the chance of a chaotic re-entry rhythm called torsades de pointes (TdP) goes up. TdP can degenerate into ventricular fibrillation, which is a cardiac arrest mechanism.

At the molecular level, the most common reason the QT interval lengthens pharmacologically is blockade of the rapid delayed-rectifier potassium channel, abbreviated I_Kr and encoded by the hERG (KCNH2) gene. Drugs and natural compounds that bind hERG with high affinity prolong repolarization. The U.S. FDA's E14 guideline (Q1 2005, harmonized with ICH) is the regulatory framework drugmakers use to assess QT liability before approval, and the hERG-binding assay is now a routine in-vitro screen in pharmaceutical and toxicology development.

Supplements do not go through E14. They are regulated under DSHEA (Dietary Supplement Health and Education Act, 1994), which means manufacturers do not need to demonstrate cardiac safety before sale. The pharmacovigilance signal comes after, through the FDA CAERS (CFSAN Adverse Event Reporting System), case reports in the peer-reviewed literature, and CRN industry reports. The result is uneven coverage: some botanicals have decades of pharmacovigilance data, others have essentially none.

Botanicals with documented QT or hERG signal

The compounds below are the ones with clinical case reports, hERG-binding data, or both. This is not a complete list; absence from this list is not safety. It is a list of names where the published evidence is concrete enough that a reasonable cardiology consult would mention them.

Licorice (Glycyrrhiza glabra), Risk: Real and dose-dependent

Licorice is the supplement-safety question where the evidence is least ambiguous. Glycyrrhizin inhibits 11-β-hydroxysteroid dehydrogenase, which leaves cortisol free to act on mineralocorticoid receptors. The downstream effect is potassium loss (hypokalemia), and hypokalemia in turn prolongs the QT interval and lowers the TdP threshold.

The European Food Safety Authority recommends an intake ceiling of approximately 100 mg glycyrrhizin per day for sustained consumption. A single licorice tea bag can deliver 30 to 50 mg. Black licorice candy (genuine, glycyrrhizin-containing, not anise-flavored) can deliver several hundred mg per serving. FDA has issued public-health advisories noting that adults over 40 eating two ounces of black licorice daily for two weeks have presented with irregular heart rhythm. The mechanism is potassium-depletion-mediated QT prolongation, not direct hERG block.

Deglycyrrhizinated licorice (DGL) products have the glycyrrhizin removed and do not carry this risk. If you use licorice for GI or adrenal support, DGL is the safer form.

Ephedra (Ephedra sinica, ma huang), Banned in the U.S. for cause

Ephedra-containing supplements were removed from the U.S. market by FDA in 2004 after a cluster of cardiovascular adverse events. Ephedrine alkaloids drive sympathetic-nervous-system activation, which raises heart rate, blood pressure, and contributes to ischemic and arrhythmic events. Ephedra remains available outside the U.S. and through illicit channels. If you encounter it abroad or as an undeclared adulterant in a weight-loss or performance product, treat it as contraindicated with any pre-existing cardiac condition.

Bitter orange (Citrus aurantium / synephrine), The ephedra successor

After ephedra was banned, the supplement industry shifted to bitter-orange-derived synephrine for many of the same use cases (weight loss, energy, athletic stim). Synephrine is a β-adrenergic agonist with structural similarity to ephedrine. Published case reports describe arrhythmia, myocardial infarction, and ischemic events associated with bitter-orange products, particularly when combined with caffeine. The literature is smaller than for ephedra and conclusions are less firm, but the mechanism overlaps.

If you take a pre-workout or fat-burner blend, check the label for Citrus aurantium, synephrine, p-synephrine, or m-synephrine.

Yohimbine (Pausinystalia yohimbe), α2-blockade with cardiac visibility

Yohimbine is an α2-adrenergic antagonist. Removing the inhibitory α2 receptor's brake on norepinephrine release produces a sympathetic-tone surge that can cause hypertension, tachycardia, panic-like symptoms, and in case-report literature, ventricular arrhythmias. The effect is dose-dependent. Yohimbine is sold as an erectile-dysfunction and weight-loss supplement at retail; the marketed doses are typically 2.5 to 10 mg, but pre-workout blends can stack it with caffeine and synephrine in ways that compound the cardiovascular load.

Kratom (Mitragyna speciosa), hERG block at higher doses

Kratom alkaloids (mitragynine and 7-hydroxymitragynine) have been shown in in-vitro studies to inhibit hERG channels at concentrations achievable in heavy users. The clinical translation is uncertain: most kratom-associated cardiac events in the published case-report literature involve polypharmacy (kratom + opioids, kratom + stimulants) rather than kratom monotherapy. FDA has not taken final action on kratom but maintains an Import Alert. If you use kratom and are also on a QT-prolonging prescription, this is a combination worth a cardiology conversation.

Hawthorn (Crataegus spp.), Mostly favorable but worth a note

Hawthorn is a venerable cardiotonic with the unusual property of being one of the few supplements where the European Medicines Agency has issued a structured monograph (HMPC). The clinical evidence supports modest benefit in early-stage heart failure (NYHA Class I-II). The relevant caveat for this article: hawthorn extracts have been shown to mildly prolong cardiac repolarization in some preclinical models, though the clinical signal in RCTs has been benign at standard doses. The interaction risk is greater for hawthorn + digoxin (additive positive inotropy) than for hawthorn-driven QT events.

Grapefruit (technically not a supplement), But it lives here

Grapefruit and grapefruit-juice furanocoumarins inhibit intestinal CYP3A4 enzymes. The list of QT-prolonging drugs whose serum concentrations rise with concurrent grapefruit intake is long and includes amiodarone, dronedarone, several statins, the antifungal azoles (itraconazole, ketoconazole), and erythromycin. Grapefruit itself does not prolong QT. It raises the blood level of the drugs that do. This is the most under-appreciated cardiac-pharmacology interaction in dietary intake.

Pomelo and Seville orange share the same furanocoumarin chemistry. Sweet orange does not.

Drug-supplement combinations that drive most reported events

When CAERS or peer-reviewed case reports describe a supplement-related QT event, the mechanism is rarely supplement-only. It is usually a stack: a QT-prolonging prescription drug, a supplement that depletes potassium or magnesium, and sometimes a metabolic perturbation (vomiting, diarrhea, dehydration) that lowers serum potassium acutely.

Supplements with a defensible cardioprotective signal

The flip side of supplement cardiac safety is the small set of compounds where the evidence for cardiovascular benefit is robust enough to take seriously. None of these are magic. All have plausible mechanisms and meta-analytic evidence beyond a single RCT.

Omega-3 (EPA + DHA from marine sources), Evidence: 7.5/10

The REDUCE-IT trial (2018, NEJM) showed icosapent ethyl 4 g/day reduced major adverse cardiovascular events in statin-treated patients with elevated triglycerides. Earlier trials with mixed EPA/DHA were less consistent. The mechanistic story includes mild membrane-stabilizing effects, anti-inflammatory action, and triglyceride lowering. The relevant note for this article: EPA at high dose has been shown in some studies to slightly lengthen QT interval as a class effect, but the clinical risk is judged low to negligible. Most experts treat omega-3 as net-favorable for cardiac safety.

Magnesium, Evidence: 8.0/10 (as electrolyte, not as cure)

Magnesium is the electrolyte that most reliably shortens a prolonged QT interval. Intravenous magnesium is the first-line treatment for acute torsades. Oral magnesium supplementation in chronic low-magnesium states (chronic diuretic use, alcohol use disorder, malabsorption) is recommended by AHA. Most adults eating a varied diet do not need supplemental magnesium for cardiac protection. Those on diuretics or with documented hypomagnesemia do.

CoQ10 (ubiquinone / ubiquinol), Evidence: 6.0/10

The Q-SYMBIO trial (2014) showed CoQ10 100 mg three times daily reduced mortality in chronic heart failure patients. Subsequent meta-analyses have been somewhat mixed but generally supportive. The mechanism is mitochondrial-respiratory-chain support. CoQ10 is also used to mitigate statin-associated muscle symptoms, where the evidence is weaker but the risk profile is low.

Taurine, Evidence: 5.5/10

Taurine is included in the energy-drink ingredient deck for branding reasons, not for the cardiac evidence; the clinically interesting work on taurine is in congestive heart failure (Japanese investigators have run several small trials showing benefit). The case for taurine supplementation in healthy adults is thin. The case for taurine in late-stage CHF is plausible but not first-line.

How to read the safety literature when your supplement is not on this list

This article names the compounds with the clearest evidence. Most supplement-cardiac questions you will encounter in practice involve botanicals that have either no published cardiac literature, or only one or two case reports of uncertain causality. Here is the decision framework we use editorially:

1. Check the FDA CAERS database. Search the supplement name and look at the cardiac event categories. CAERS is voluntary reporting so absence is not safety, but presence is signal.
2. Check Natural Medicines or similar curated databases for hERG / QT entries. Natural Medicines, Memorial Sloan Kettering's About Herbs database, and the European Medicines Agency HMPC monographs are the three sources we cross-reference editorially. A single source with a positive signal is worth a follow-up; concurrence across two is strong.
3. Read the case reports, not just the meta-analyses. Meta-analyses average out rare events. The literature on supplement-associated cardiac events is dominated by case reports, and the pattern of polypharmacy in those case reports is the actionable information.
4. If you are on a QT-prolonging prescription, default to caution. The CredibleMeds list (crediblemeds.org) is the published reference for QT-prolonging prescription drugs, maintained by the University of Arizona Center for Education and Research on Therapeutics. If your prescription is on the Known Risk list, treat any new supplement as something to clear with the prescribing clinician.

A practical decision frame

If we had to compress this into a four-line decision frame:

• If you have a known cardiac history (long-QT syndrome, prior arrhythmia, heart failure, structural disease) and are considering any new supplement: confirm with your cardiologist that the supplement is not on the CredibleMeds-adjacent literature.
• If you are on a QT-prolonging prescription: avoid licorice, ephedra, bitter orange, yohimbine, and high-dose kratom. Default to caution on grapefruit-containing beverages.
• If you are healthy and on no QT-active medications: the named botanicals above are still worth knowing, but you have wider latitude.
• If you supplement for cardiovascular protection: omega-3, magnesium (when indicated), and CoQ10 (in CHF) are the three compounds with the best evidence. The rest is marketing.

FAQs